Emergent Biosolutions Inc
$ 10.96
0.09%
24 Feb - close price
- Market Cap 584,195,000 USD
- Current Price $ 10.96
- High / Low $ 11.21 / 10.73
- Stock P/E 8.30
- Book Value 11.05
- EPS 1.32
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.14 %
- 52 Week High 14.06
- 52 Week Low 4.02
About
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
Analyst Target Price
$13.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-06 | 2025-04-29 | 2025-03-04 | 2024-11-06 | 2024-08-06 | 2024-05-01 | 2024-03-06 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-27 |
| Reported EPS | 1.06 | 0.16 | 0.71 | -0.5775 | 1.37 | -2.32 | 0.59 | -0.77 | -0.54 | -1.06 | -3.17 | -0.31 |
| Estimated EPS | 0.0467 | -0.1 | 0.7 | -0.4957 | 0.14 | -0.94 | -0.86 | -0.19 | -0.22 | -0.49 | -1.24 | 0.04 |
| Surprise | 1.0133 | 0.26 | 0.01 | -0.0818 | 1.23 | -1.38 | 1.45 | -0.58 | -0.32 | -0.57 | -1.93 | -0.35 |
| Surprise Percentage | 2169.8073% | 260% | 1.4286% | -16.5019% | 878.5714% | -146.8085% | 168.6047% | -305.2632% | -145.4545% | -116.3265% | -155.6452% | -875% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.855 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EBS
2026-02-21 02:51:22
This article identifies three stocks—Lake Shore Bancorp (LSBK), Emergent BioSolutions (EBS), and MINISO Group Holdings (MNSO)—that AI analysis projects to have over 20% upside potential. LSBK is noted for financial health, EBS for public health focus despite challenges, and MNSO for strong retail performance. The analysis relies on the TipRanks AI Analyst Top Stocks Screener Tool for investment insights.
2026-02-20 07:57:41
The New York Attorney General has filed a complaint against Robert Kramer, the former CEO of Emergent BioSolutions Inc., alleging insider trading related to the sale of company stock while he possessed material nonpublic information about contamination issues with COVID-19 vaccine manufacturing. This action signals a potential shift in securities enforcement, with state authorities increasingly prosecuting cases traditionally handled by federal agencies. Kramer has since moved to remove the case to federal court, arguing that the claims arise under federal law.
2026-02-14 01:27:54
Emergent BioSolutions Inc. (EBS) is analyzed as a specialty and generic drug manufacturer with a market cap of $578.86 million, focusing on public health threat solutions. Despite a recent revenue decline, the company boasts positive analyst sentiment, an average target price of $13.50, and a potential upside of 24.42%. Its robust free cash flow and strategic pipeline in vaccines and therapeutics position it for long-term growth, despite current market volatility.
2026-02-13 08:58:18
Emergent BioSolutions announced that the FDA has approved a supplemental New Drug Application (sNDA) for its NARCAN® Nasal Spray multipacks. This approval is for packaging the life-saving naloxone product in a new carrying case, aiming to increase accessibility for everyday preparedness. The company also recently received FDA approval for new packaging for NARCAN Nasal Spray to be included in a new carrying case.
2026-02-13 01:58:07
Emergent BioSolutions Inc. (NYSE: EBS) announced it will host a conference call on Thursday, February 26, 2026, at 5:00 pm Eastern Time to discuss its financial results for the fourth quarter and full year of 2025. Interested parties can access the call live via webcast or by registering in advance for telephone participation. A replay of the call will also be available on the company's investors page.
2026-02-12 22:58:35
Emergent BioSolutions (NYSE: EBS) has received FDA approval for supplemental New Drug Applications (sNDA) for new 6-count and 24-count multipack configurations of NARCAN® Nasal Spray. These multipacks are designed to facilitate higher-volume distribution to public interest customers via NARCANDirect®, enhancing accessibility for community programs and large-scale preparedness efforts. This approval complements a previous FDA approval in January 2026 for a NARCAN carrying case, further strengthening the company's commitment to combating opioid overdose deaths.
